Citius Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 22
- Market Cap
- $106.9M
- Website
- http://www.citiuspharma.com
- Introduction
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids
- Conditions
- Hemorrhoids
- Interventions
- Drug: Monad 1Drug: Monad 2Drug: Monad 3Drug: Combination - CITI-002 (low dose)Drug: Combination - CITI-002 (high dose)
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Citius Pharmaceuticals, Inc.
- Target Recruit Count
- 304
- Registration Number
- NCT05348200
- Locations
- 🇺🇸
Site #01, Huntsville, Alabama, United States
🇺🇸Site #07, Tucson, Arizona, United States
🇺🇸Site #06, Chula Vista, California, United States
Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids
- Conditions
- Hemorrhoids
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Citius Pharmaceuticals, Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT02689856